Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma proteomic profiling in patients with atopic dermatitis treated with nemolizumab
jRCT1030230474Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Temporal variation of plasma proteomic factors and Patient clustering based on proteomic trajectories. Started Nov 2023; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1030230474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230474.